TECOGEN (TGEN) CEO Rangesh Abinand purchases 3,000 common shares

Rhea-AI Filing Summary

TECOGEN INC. Chief Executive Officer and Chief Financial Officer Rangesh Abinand reported an open-market purchase of 3,000 shares of common stock on 2026-03-20 at a price of $2.298 per share. Following this transaction, his directly reported holdings increased to 67,193 shares of common stock.

According to a footnote, 2,500 of the purchased shares were acquired by Rangesh Abinand and 500 shares were acquired by his daughter, all reported in this Form 4. The transaction is classified as a non-derivative, open-market purchase.

Insider Trade Summary

Net Buyer: 3,000 shares ($6,894)

Net Buy 1 txn

Insider Rangesh Abinand

Role Chief Executive Officer

Bought 3,000 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,000	$2.298	$7K

Holdings After Transaction: Common Stock — 67,193 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rangesh Abinand

(Last) (First) (Middle)

76 TREBLE COVE ROAD

(Street)

NORTH BILLERICA MASSACHUSETTS 01862

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TECOGEN INC. [ TGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Executive Officer		Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		P		3,000(1)	A	$2.298	67,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 2,500 shares acquired by Abinand Rangesh and 500 shares acquired by daughter

Remarks:

	/s/ Abinand Rangesh	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TECOGEN INC. (TGEN) report for Rangesh Abinand?

TECOGEN reported that Chief Executive Officer Rangesh Abinand bought 3,000 shares of common stock in an open-market transaction on March 20, 2026. The filing classifies this as a non-derivative purchase under code P, indicating a standard market buy.

At what price did Rangesh Abinand purchase TECOGEN (TGEN) shares in this Form 4?

Rangesh Abinand purchased TECOGEN common stock at a price of $2.298 per share. The transaction involved 3,000 shares in total and is described as an open-market or private transaction, coded as a purchase under the Form 4 reporting rules.

How many TECOGEN (TGEN) shares does Rangesh Abinand hold after this transaction?

After this reported transaction, Rangesh Abinand directly holds 67,193 shares of TECOGEN common stock. This figure reflects his position immediately following the 3,000-share open-market purchase disclosed in the Form 4 insider trading report.

How were the 3,000 TECOGEN (TGEN) shares allocated between Rangesh Abinand and his daughter?

A Form 4 footnote explains that 2,500 of the purchased TECOGEN shares were acquired by Rangesh Abinand and 500 shares were acquired by his daughter. All 3,000 shares are reported together in this insider filing for regulatory disclosure purposes.

What does transaction code P indicate in the TECOGEN (TGEN) Form 4 filing?

Transaction code P in this Form 4 indicates a purchase in an open market or private transaction. For TECOGEN, it confirms that the 3,000 shares reported for Rangesh Abinand were acquired through a straightforward buying transaction rather than an option exercise or gift.

Does the TECOGEN (TGEN) Form 4 show any derivative or option activity for Rangesh Abinand?

The Form 4 indicates no derivative transactions for this event, focusing solely on a non-derivative common stock purchase. The derivative summary is empty, meaning the filing does not report any option exercises, conversions, or other derivative-related activity for this date.